Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Skin Aging
Interventions
DRUG

Botulinum Toxin Type A

Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines

DRUG

Placebo

Placebo, Dose B; dose applied to the lateral canthal lines

Trial Locations (1)

33146

Dermatology Research Institute, Coral Gables

All Listed Sponsors
lead

Revance Therapeutics, Inc.

INDUSTRY

NCT01776606 - Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines | Biotech Hunter | Biotech Hunter